|
Molnupiravir
(Merck) |
Paxlovid
(Pfizer) |
|
|
Authorized Use(s)
|
Treatment of mild to moderate symptoms
|
Treatment of mild to moderate symptoms
|
|
Age Eligibility
|
Ages 18 and older
|
Ages 12 years and older
|
|
Weight Eligibility
|
No weight requirement
|
88 pounds or more
|
|
Other Criteria for Treatment
|
Test Positive for SARS-CoV-2
Be within 5 days of the start of symptoms Not be hospitalized |
Test Positive for SARS-CoV-2
Be within 5 days of the start of symptoms Not be hospitalized |
|
Other Criteria for Prevention
|
|
|
|
Letter of Authorization
|
||
|
EUA Fact Sheet
|